908 Devices Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MASS research report →
Range $14 – $14
Price Chart
About the company
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample.
- CEO
- Kevin J. Knopp
- IPO
- 2020
- Employees
- 172
- HQ
- Burlington, MA, US
Get TickerSpark's AI analysis on MASS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $360.52M
- P/E
- -14.87
- PEG
- 0.01
- P/S
- 5.92
- P/B
- 2.57
- EV/EBITDA
- -16.07
- Div Yield
- 0.00%
- Gross Margin
- 50.79%
- Op Margin
- -42.96%
- Net Margin
- -36.71%
- ROE
- -17.42%
- ROIC
- -15.95%
Latest fiscal year · YoY change
- Revenue
- $56.20M-5.8%
- Gross Profit
- $26.80M-10.5%
- Op Income
- $-24,180,000
- Net Income
- $-36,639,000+49.3%
- EPS
- $-1.01+52.4%
- OCF Growth
- +21.7%
- FCF Growth
- +20.1%
- 52W High
- $13.35
- 52W Low
- $5.03
- 50D MA
- $11.12
- 200D MA
- $8.64
- Beta
- 0.63
- RSI (14)
- 35
- Avg Volume
- 390.41K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
908 Devices delivered record Q3 revenue and device shipments, raised the low end of full-year guidance, and highlighted momentum in NIRLab, ProtectIR, and next-gen MX908.· November 10, 2026
- Q3 revenue was $19 million, up 35% year over year, with adjusted EBITDA loss of $1.7 million.
- The company shipped more than 300 devices, a record quarter, and ended with an installed base of about 4,400 devices.
- Management raised full-year 2026 revenue guidance to $68.5 million to $70 million and kept adjusted EBITDA loss guidance at the mid-single-digit millions.
- NIRLab ramped quickly: about 100 devices sold in the quarter, more than half to customers new to NIRLab, and usage reached more than 1 million cumulative scans.
- International business was a meaningful contributor, with international customers representing 40% of Q3 revenue, double the prior year.
Total revenue was $19 million in Q3 2026, up 35% from $14 million in Q3 2025. Handheld product and service revenue was $17.8 million, up 35% from $13.2 million a year ago; OEM and funded partnership revenue was $1.1 million, up 42% from $0.8 million; recurring revenue was $5.1 million, up $0.2 million year over year and 27% of total revenue. Gross profit was $10 million versus $7.4 million last year, with gross margin at 53% and adjusted gross margin at 58% (down 40 basis points). Net loss from continuing operations was $4.6 million versus $14.9 million last year, and adjusted EBITDA loss was $1.7 million versus $1.8 million. The company used $2.4 million of cash in the quarter and ended with $99.1 million in cash, cash equivalents and marketable securities, with no debt. Full-year 2026 revenue guidance was raised to $68.5 million to $70 million, implying 22% to 25% growth; handheld product and service revenue is expected to be $65.5 million to $67 million, OEM and funded partnerships about $3 million, adjusted gross margin mid- to high-50% range, and adjusted EBITDA loss in the mid-single-digit millions. Management did not include AVCAD program revenue in guidance.
Kevin Knopp characterized Q3 as a strong quarter across the board and framed the company as making progress on three 2026 priorities: scaling proven platforms, extending platform leadership, and strengthening revenue durability through connected services. He emphasized record device shipments, international expansion, NIRLab adoption, and the next-generation MX908 as a 2027 growth driver. His tone was confident and constructive, with repeated emphasis on pipeline strength, operating discipline, and long-term category leadership.
Joe Griffith focused on the financial performance and guide raise, pointing to 35% revenue growth, stable 53% gross margin, 58% adjusted gross margin, and a much smaller net loss versus the prior year. He noted the quarter’s operating expense decline was helped by an $11 million noncash reduction in contingent consideration expense, partially offset by a $2.8 million increase in SG&A that included NIRLab costs. On capital, he highlighted $99.1 million in cash and no debt, and he reiterated guidance for 22% to 25% full-year revenue growth and a mid-single-digit million adjusted EBITDA loss.
Analysts pressed on whether Q3 had any pull-forward or customer concentration issues, and management said there was no order shift or unusual movement; Joe Griffith said the guide raise mainly reflects Q3 performance and that Q4 would need about 20% growth at the midpoint, or closer to 24% for the high end. Questions also focused on NIRLab, where management said more than half of Q3 placements were to customers new to NIRLab and that the product could become a $5 million-plus business in 2027. On AVCAD, management said testing with the U.S. Army’s capability office is a constructive signal for a potential commercial-off-the-shelf path in 2027, with better economics than OEM-style revenue if that route is chosen.
The call showed multiple growth levers moving at once: record device shipments, international momentum, NIRLab adoption, and early signs of demand for next-generation MX908. Management also sounded encouraged by connected-services monetization and by the possibility that AVCAD could convert into a more favorable COTS opportunity in 2027. The balance sheet remains strong with $99.1 million in cash and no debt.
Q4 still needs execution to hit the top end of guidance, and management said stronger fourth-quarter growth would require closing key opportunities, especially in VipIR and mass spec. Gross margin was flat year over year at 53%, while adjusted gross margin slipped 40 basis points due to product mix and lower-margin international revenue. Management also flagged lingering softness in mass spec service tied to lost defense funding, although they expect that impact to ease as they lap it in Q4.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 79.1%
- Shares Outstanding
- 41.58M
- Float Shares
- 32.89M
of shares held by institutions
114 13F filers
Buy/sell ratio 0.40. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| First Light Asset Management, LLC | 6.28M | ▲ 210.24K |
| Awm Investment Company, Inc. | 4.74M | ▼ 143.00K |
| Ark Investment Management LLC | 2.09M | ▲ 66.91K |
| Blackrock, Inc. | 2.05M | ▲ 100.92K |
| Needham Investment Management LLC | 1.82M | ▲ 580.62K |
| Vanguard Group Inc | 1.47M | ▲ 49.13K |
| Vanguard Capital Management LLC | 1.32M | ▲ 32.70K |
| American Century Companies Inc | 1.17M | ▲ 811.80K |
| First Eagle Investment Management, LLC | 875.79K | ▼ 54.19K |
| Geode Capital Management, LLC | 798.86K | ▲ 37.06K |
| Granahan Investment Management, LLC | 692.09K | ▼ 2.98K |
| Lord, Abbett & Co. LLC | 688.49K | ▲ 688.49K |
Held by 127 ETFs
Biggest fund positions in MASS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Brown Christopher D. | other | 54,318 |
| Nov 17, 26 | Brown Christopher D. | other | 54,318 |
| Nov 4, 26 | Brown Christopher D. | sell | 30,000 |
| Oct 7, 26 | Brown Christopher D. | other | 60,000 |
| Oct 7, 26 | Brown Christopher D. | sell | 30,000 |
| Oct 7, 26 | Brown Christopher D. | other | 60,000 |
| Oct 6, 26 | Griffith Joseph H. IV | sell | 5,000 |
| Sep 29, 26 | AWM Investment Company, Inc. | sell | 18,000 |
| Sep 23, 26 | AWM Investment Company, Inc. | sell | 1,000 |
| Sep 24, 26 | AWM Investment Company, Inc. | sell | 24,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MASS coverage
Recent articles, reports, and earnings notes.
No research on MASS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MASS report →What 908 Devices (MASS) Said on Its Q3 Earnings Call
defenseworld.net · Nov 13
908 Devices: Solid Q3 Results
seekingalpha.com · Nov 10
908 Devices Inc. (MASS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
What 908 Devices (MASS) Said on Its Q3 Earnings Call
marketbeat.com · Nov 10
908 Devices Inc. (MASS) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 10
908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue
businesswire.com · Nov 10
908 Devices to Participate in the Stifel 2026 Healthcare Conference
businesswire.com · Nov 4
Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity
seekingalpha.com · Oct 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.